43 research outputs found

    Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

    Get PDF
    Background Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. Methods Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. Results A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55). Conclusions Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.

    Badanie właściwości dynamicznych tokarki do gwintów falistych

    No full text
    Paper present results of experimental investigations on dynamic properties of rope threading lathe TAE 45N. Prototype of this uniquely designed machine tool was delivered for the tests focused on finding dominant mode shape. Influence of the dominant mode on the cutting process is determined. Significant velocity and acceleration of headstock, during machining, can result in high vibration amplitudes, and its influence was estimated.W artykule przedstawiono wyniki badań doświadczalnych unikatowej tokarki do gwintów falistych TAE 45N. Badania prototypu tej obrabiarki zostały przeprowadzone w celu wyznaczenia dominującej postaci drgań, oddziałujących na realizację procesu skrawania. Przyjęty cel wynika głównie z zastosowanej kinematyki obróbki charakteryzującej się dużą prędkością i przyspieszeniem głowicy narzędziowej, w trakcie jej realizacji

    The device for testing the spring mechanisms to a drive of medium voltage switch-disconnectors

    No full text
    Integracja zaawansowanych przetworników pomiarowych, technik cyfrowego sterowania napędami oraz metod bezpiecznego programowania pozwala automatyzować nie tylko procesy wytwórcze, lecz także złożone i czasochłonne procedury testowania i badania wyrobów. Przykładem takiej zintegrowanej aplikacji pomiarowej jest opracowane w PIAP urządzenie testujące mechanizmy sprężynowe do napędu rozłączników średnich napięć, które zostało wdrożone w 2009 r. w firmie ABB Oddział w Przasnyszu. Urządzenie zdejmuje charakterystyki momentu obrotowego w funkcji kąta obrotu, przy załączaniu i wyłączaniu mechanizmu sprężynowego. Uzyskano dokładność i wydajność testowania nieosiągalne przy manualnym zdejmowaniu charakterystyk. Wyeliminowano także zagrożenia dla obsługi przy operowaniu mechanizmami sprężynowymi kumulującymi znaczne energie.The integration of advanced measuring converters, techniques of digital control for drives and methods of safe programming permits to automate not only productive processes, but also complex and time-consuming testing procedures and investigations of products. The example of such integrated measuring application is worked out in PIAP the device for testing spring mechanisms to a drive of medium voltage switch-disconnectors which were implemented in 2009 in the division of ABB in Przasnysz. The device takes off torque characteristics as function of turn angle, when enclosing and disengaging of spring mechanism. The accuracy and testing rate obtained were unattainable using characteristics taken off manually. Risks to service staff by operating the spring mechanisms also were eliminated
    corecore